The partnership aims to integrate Better Therapeutics’ ApsyreRx digital behavioral treatment into Glooko’s diabetes management platform. Better Therapeutics designed AspyreRx to treat type 2 diabetes. The FDA authorized AspyreRx as a prescription digital therapeutic for diabetes in July.
Palo Alto, California-based Glooko’s current platforms enable patients to share diabetes data with healthcare providers. That includes blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight.
“We are very pleased to partner with Better Therapeutics to add AspyreRx to the Glooko platform,” said Russ Johannesson, Glooko CEO. “This partnership will facilitate access to an important new treatment option for healthcare providers in the Glooko network, enabling them to better manage their patient populations and enhance health outcomes for patients with T2D.”
According to the companies, the collaboration could enable healthcare providers in the U.S. using the Glooko platform to identify suitable patients for AspyreRx treatment. It could also facilitate prescriptions and track patients throughout their treatment.
Glooko’s reach in the U.S. expands to more than 3.4 million people with diabetes. Nearly 5,000 clinic locations utilize the company’s platforms, according to a news release. Users of the Glooko healthcare provider platform can now access AspyreRx as a new treatment option. Additionally, using Glooko’s “precision engagement” functionality, the platform flags suitable patient candidates for providers.
“Glooko is an ideal partner for us to support the adoption of AspyreRx, given the extensive overlap between providers using the Glooko platform and those we have identified as early adopters for AspyreRx,” said Frank Karbe, Better Therapeutics CEO. “Glooko’s precision engagement has the potential to accelerate access to AspyreRx for patients who may benefit from this innovative new treatment.”
